Ameriprise Financial Inc. Trims Stock Position in IQVIA Holdings Inc. $IQV

Key Points

• Ameriprise Financial Inc. reduced its stake in IQVIA Holdings Inc. by 10.8%, selling 104,637 shares, which left them with 866,496 shares valued at approximately $152.76 million.
• Institutional investors hold 89.62% of IQVIA's stock, with a variety of hedge funds actively trading their positions recently, some significantly increasing their stakes.
• IQVIA reported a quarterly earnings per share of $2.81, exceeding estimates, and has set FY 2025 guidance at 11.750-12.050 EPS.

Ameriprise Financial Inc. decreased its position in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 10.8% in the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 866,496 shares of the medical research company's stock after selling 104,637 shares during the period. Ameriprise Financial Inc. owned 0.50% of IQVIA worth $152,758,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of the stock. Brighton Jones LLC boosted its stake in shares of IQVIA by 244.4% during the 4th quarter. Brighton Jones LLC now owns 3,575 shares of the medical research company's stock worth $703,000 after acquiring an additional 2,537 shares in the last quarter. First Trust Advisors LP raised its holdings in IQVIA by 15.3% in the fourth quarter. First Trust Advisors LP now owns 59,966 shares of the medical research company's stock valued at $11,784,000 after acquiring an additional 7,969 shares in the last quarter. T. Rowe Price Investment Management Inc. increased its stake in IQVIA by 27.5% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 2,520 shares of the medical research company's stock valued at $496,000 after purchasing an additional 544 shares during the last quarter. Syon Capital LLC grew its position in shares of IQVIA by 34.0% during the fourth quarter. Syon Capital LLC now owns 1,138 shares of the medical research company's stock worth $224,000 after acquiring an additional 289 shares during the last quarter. Finally, Adage Capital Partners GP L.L.C. lifted its holdings in shares of IQVIA by 63.7% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 38,860 shares of the medical research company's stock valued at $7,636,000 after buying an additional 15,127 shares during the period. Hedge funds and other institutional investors own 89.62% of the company's stock.

Analysts Set New Price Targets

IQV has been the subject of a number of research reports. JPMorgan Chase & Co. decreased their target price on IQVIA from $232.00 to $177.00 and set an "overweight" rating for the company in a report on Monday, May 19th. Citigroup reaffirmed a "neutral" rating on shares of IQVIA in a research note on Thursday, May 22nd. Truist Financial increased their price objective on IQVIA from $209.00 to $235.00 and gave the stock a "buy" rating in a research note on Wednesday, July 23rd. Robert W. Baird raised their price target on IQVIA from $159.00 to $196.00 and gave the stock a "neutral" rating in a research note on Wednesday, July 23rd. Finally, Mizuho lifted their price objective on IQVIA from $190.00 to $225.00 and gave the stock an "outperform" rating in a report on Friday, July 25th. Seventeen investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $228.62.

Insiders Place Their Bets

In other news, insider Eric Sherbet sold 5,800 shares of the business's stock in a transaction on Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total transaction of $1,102,290.00. Following the completion of the sale, the insider owned 27,178 shares of the company's stock, valued at $5,165,178.90. The trade was a 17.59% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Keriann Cherofsky sold 549 shares of the business's stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total transaction of $105,149.97. Following the completion of the sale, the insider owned 2,910 shares in the company, valued at approximately $557,352.30. The trade was a 15.87% decrease in their position. The disclosure for this sale can be found here. Insiders own 1.60% of the company's stock.

IQVIA Stock Performance

Shares of NYSE IQV traded down $0.07 during midday trading on Thursday, reaching $188.73. The company's stock had a trading volume of 732,346 shares, compared to its average volume of 1,943,112. The stock has a market capitalization of $32.08 billion, a P/E ratio of 27.30, a PEG ratio of 2.06 and a beta of 1.30. The firm has a 50 day moving average price of $175.64 and a 200-day moving average price of $168.11. IQVIA Holdings Inc. has a 12-month low of $134.65 and a 12-month high of $252.88. The company has a debt-to-equity ratio of 2.45, a current ratio of 0.84 and a quick ratio of 0.84.

IQVIA (NYSE:IQV - Get Free Report) last released its earnings results on Tuesday, July 22nd. The medical research company reported $2.81 EPS for the quarter, beating analysts' consensus estimates of $2.77 by $0.04. The business had revenue of $4.02 billion for the quarter, compared to analysts' expectations of $3.96 billion. IQVIA had a return on equity of 30.05% and a net margin of 7.88%.The firm's revenue was up 5.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.64 earnings per share. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. As a group, equities analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.